NanoViricides Inc NNVC shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for Respiratory Syncytial Virus (RSV).
The company reported on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV.
NV-387 is the active ingredient of NV-CoV-2, the company's drug for COVID and possibly long COVID.
As previously reported, it is already in Phase 1a/1b human clinical trials for evaluating safety in healthy volunteers and of safety and preliminary efficacy in COVID patients.
The company says that NV-387 can be advanced into Phase 2 studies against RSV once the current Phase 1 studies of NV-CoV-2 are completed. This will significantly speed up the development of the RSV drug, save costs, and improve return on investments.
Two vaccines have recently been approved for RSV prophylaxis. GSK plc's GSK Arexvy and Pfizer Inc's PFE Abrysvo (for use in adults over 60 years of age and both reduced severity of RSV infection.
There are no vaccines currently approved for infants and children. There are no effective therapeutics for RSV to date.
Price Action: NNVC shares are up 27.70% at $1.80 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
